State's health benefits agency running out of money
BOSTON (SHNS) – The state agency that oversees health insurance for 460,000 public employees, retirees and their dependents is on track to run out of money to pay claims on May 12, a full seven weeks before the end of the fiscal year.
During a briefing to Group Insurance Commission members Thursday, Executive Director Matthew Veno said rising provider prices and increased utilization of prescription benefits, including for GLP-1 weight loss drugs, had caused the commission to run an average $20 million monthly deficit this fiscal year.
With the fiscal year set to end June 30, the commission is counting on taxpayers to cover its deficit and has a $240 million appropriation request pending before the Legislature.
The appropriation was the largest single request in a $756 million spending bill Gov. Maura Healey filed in early April.
The House Ways and Means Committee released its fiscal 2026 annual budget Wednesday, and Veno expressed hope Thursday that the panel will quickly turn attention to the supplemental budget. He said he was working with Healey's team to make sure lawmakers understand 'the urgency of moving this legislation.'
'What we want to do is avoid disruption to our members, our health plans and to the providers that rely on our prompt payment of claims,' he said. 'And we are likewise in the process of meeting with our health plans to make sure that we're prepared to manage any disruption that may come along our way if there's delayed action.'
While predicting timetables for legislative action in Massachusetts is perilous, Veno said he believed that it was 'unlikely that the supplemental budget will not be enacted in a timely manner.'
'But it is certainly a cause on my part for concern and focus since by our current projections and our current appropriation is sufficient to make claims only through the 12th of May 2025,' he added.
Commission members had no questions for Veno about the deficit, apart from a Bobbi Kaplan inquiry about whether the GIC might need to adjust its fiscal 2026 budget request to reflect the higher fiscal 2025 costs. Veno said no adjustment is necessary.
'While we have been consistently running a deficiency, it's been pretty consistent. So we were able to build an FY '26 budget that reflects those trends,' he said.
There's been steady growth in the major state spending account in recent years, adding pressure in the overall state budget and creating another touchpoint for those who believe stronger action is needed to address health-related costs.
The GIC's 'plan premium and costs' are projected at $2.16 billion for fiscal 2025 and Healey requested a $2.4 billion allocation for fiscal 2026, a funding level also recommended by the House Ways and Means Committee. Expenses from the account totaled $1.83 billion in fiscal 2022, according to state finance documents.
The GIC provides health insurance to state employees and retirees and their dependents and survivors. It has 280,000 subscribers and 460,000 members.
In January, Veno flagged the agency's budget shortfalls as a going concern.
'This is the largest variance that we've seen in at least a decade, and this is consistent across all of our plans, and is driven primarily by rising provider prices and a couple of other topics,' he said at the time. He added, 'We don't know where this is going to head. My concern is that it is a persistent and steady trend going forward.'
The agency has a 'good list of candidates' for its open chief financial officer position, Veno said, an the annual enrollment process is 'going smoothly' with policy holders shopping around given increasing premiums. The commission also plans to offer a report in May on out-of-pocket spending trends.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
38 minutes ago
- Yahoo
707 Cayman Holdings Limited Announces Pricing of $10.0 Million Initial Public Offering
HONG KONG, June 09, 2025 (GLOBE NEWSWIRE) -- 707 Cayman Holdings Limited ('707' or the 'Company') (Nasdaq: JEM), a Hong Kong-based company that sells quality apparel products and provides supply chain management total solutions, today announced the pricing of its initial public offering (the 'Offering') of an aggregate 2,500,000 ordinary shares at a public offering price of $4.00 per share for total gross proceeds of $10.0 million, before deducting underwriting discounts and offering expenses. The Company is offering 1,750,000 ordinary shares and the selling shareholder is offering in aggregate 750,000 ordinary shares. The Company will not receive any proceeds from any sale of shares by the selling shareholder. The shares are scheduled to begin trading on the Nasdaq Capital Market on June 9, 2025, under the ticker symbol 'JEM.' The Offering is expected to close on or about June 10, 2025, subject to customary closing conditions. Bancroft Capital, LLC is acting as sole underwriter for the Offering. Troy Gould PC is acting as U.S. legal counsel to the Company, and Sichenzia Ross Ference Carmel LLP is acting as U.S. legal counsel to Bancroft Capital, LLC. This Offering is being conducted pursuant to the Company's registration statement on Form F-1, as amended (File No. 333-281949), which was filed with the United States Securities and Exchange Commission (the 'SEC') and was declared effective on June 9, 2025. The Offering of the securities is being made only by means of a prospectus. Electronic copies of the final prospectus relating to the Offering may be obtained by visiting the SEC's website located at or by contacting Bancroft Capital, LLC, 501 Office Center Drive, Suite 130, Fort Washington, PA 19034, Attention: Jason Diamond or email: investmentbanking@ or by telephone at 484-546-8000. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About 707 Cayman Holdings Limited 707 Cayman Holdings Limited is a Hong Kong-based company that sells quality apparel products and provides supply chain management total solutions to our customers spanning from Western Europe, North America to the Middle East. Our customers include mid-size brand owners and apparel companies that have comprehensive operations with private labels that are sold worldwide. Safe Harbor Statement This press release contains forward-looking statements that reflect our current expectations and views of future events, including but not limited to, the Company's proposed Offering. Known and unknown risks, uncertainties and other factors, including those listed under 'Risk Factors,' may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'is/are likely to,' 'potential,' 'continue' or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements. Contact: 707 Cayman Holdings Limited Contact:HBK Strategy Limited ir@ +852 2156 0223 Underwriter Contact:Bancroft Capital, LLC,501 Office Center Drive, Suite 130Fort Washington, PA 19034Email: investmentbanking@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut
Omada Health, Inc. (NASDAQ:OMDA) closed its first day of trading at $23 per share on Friday, a 21% jump from the IPO price of $19 per share. On Thursday, Omada Health priced its initial public offering of 7.9 million at $19/share. The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. The company raised $150 million in its IPO. Reuters reported Omada Health's valuation hit $1.28 billion. Omada's revenue increased 57% in the first quarter of 2025 to $55 million from $35.1 million a year earlier, according to its prospectus. For 2024, revenue rose 38% to $169.8 million from $122.8 million the previous company's net loss narrowed to $9.4 million in the first quarter from $19 million a year ago. Omada launched its initial virtual program in diabetes prevention and weight health in 2012. The company delivers virtual care between doctor visits, providing an engaging, personalized, and integrated experience for members designed to improve their health while delivering value for employers, health plans, health systems, pharmacy benefit managers (PBMs), and other entities that cover the cost of programs. According to its S-1 filing, the company had 2,000 customers and more than 679,000 members enrolled in one or more programs as of 31 March. Omada says it has supported more than 1 million members since its launch. The company expanded its virtual care programs to target prediabetes, hypertension, and musculoskeletal conditions. The company estimates that about 20 million people have benefits coverage for one or more Omada programs. According to the company's S-1 filing, this represents about 14% of the self-insured insurance market, 9% of the fully insured market, 1% of the Medicare Advantage market, and 1% of the PBM market. Wall Street Journal, citing President Wei-Li Shao, writes that Omada leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro have sparked a renewed focus on health problems that can stem from obesity. GLP-1s are expected to be a significant tailwind as more employers are rolling out reimbursement plans for the drugs, CEO Sean Duffy told WSJ. Omada, which signs contracts with employers to offer as a benefit to their workers, aims to be a complementary service that helps patients navigate taking GLP-1s. Omada's IPO is the second digital health IPO in weeks following an extended drought for the industry. In May, digital physical therapy startup Hinge Health Inc. (NYSE:HNGE) debuted on the New York Stock Exchange. Hinge Health priced its IPO of 13.7 million shares at $32 per share. Price Action: OMDA stock is trading lower by 0.43% to $22.90 premarket at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
Caris Life Sciences Announces Launch of Initial Public Offering
IRVING, Texas, June 9, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has launched the roadshow for its proposed initial public offering of its common stock. Caris has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") to offer 23,529,412 shares of its common stock to the public. In addition, Caris intends to grant the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $16.00 and $18.00 per share. Caris has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol "CAI." BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC will act as lead book-running managers for the proposed offering. Citigroup will also act as a book-running manager for the proposed offering. TD Cowen, Evercore ISI and Guggenheim Securities will act as additional book-running managers for the proposed offering. BTIG and Wolfe | Nomura Alliance will act as co-managers for the proposed offering. The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@ or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282 or by email: prospectus-ny@ A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Caris Life Sciences Media: Corporate CommunicationsCorpComm@ Investor Relations:Narendra ChokshiSenior Vice President, Corporate Developmentnchokshi@ View original content to download multimedia: SOURCE Caris Life Sciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data